{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T22:56:42Z","timestamp":1767135402441,"version":"build-2238731810"},"publisher-location":"Chichester, UK","reference-count":32,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd003685","type":"reference-entry","created":{"date-parts":[[2003,11,21]],"date-time":"2003-11-21T17:14:00Z","timestamp":1069434840000},"source":"Crossref","is-referenced-by-count":6,"title":["Rofecoxib for rheumatoid arthritis"],"prefix":"10.1002","author":[{"given":"S","family":"Garner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Fidan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Frankish","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Judd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Towheed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Wells","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Tugwell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,7,22]]},"reference":[{"issue":"21","key":"10.1002\/14651858.CD003685-BIB1|cit1","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJM200011233432103","article-title":"Comparison of upper gastrointestinal toxicity of Rofecoxib and Naproxen in patients with rheumatoid arthritis. The VIGOR trial","volume":"343","author":"Bombardier","year":"2000","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"10.1002\/14651858.CD003685-BIB2|cit2","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/S0149-2918(99)80048-4","article-title":"The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Phase II Rofecoxib Rheumatoid Arthritis Study Group","volume":"21","author":"Schnitzer","year":"1999","journal-title":"Clinical Therapeutics"},{"issue":"9","key":"10.1002\/14651858.CD003685-BIB3|cit3","first-page":"1670","article-title":"COX-2 specific inhibition with MK-096625 or 50 mg Q.D. does not increase intestinal permeability [abstract]","volume":"93","author":"Bjarnason","year":"1998","journal-title":"American journal of Gastroenterology"},{"issue":"6","key":"10.1002\/14651858.CD003685-BIB4|cit4","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1046\/j.1365-2036.1999.00529.x","article-title":"Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen","volume":"13","author":"Lanza","year":"1999","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"10","key":"10.1002\/14651858.CD003685-BIB5|cit5","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/S0149-2918(99)80045-9","article-title":"Comparison of rofecoxib and celecoxib, two cyclooxygenase-2 inhibitors in postoperative dental pain: a randomized, placebo- and active-comparator-controlled clinical trial","volume":"21","author":"Malmstrom","year":"1999","journal-title":"Clinical Therapeutics"},{"key":"10.1002\/14651858.CD003685-BIB6|cit6","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1136\/gut.47.4.527","article-title":"Cox-2 inhibition with rofecoxib does not increase intestinal permeability in healthy subjects: a double-blind cross-over study comparing rofecoxib with placebo and indomethacin","volume":"47","author":"Sigthrosson","year":"2000","journal-title":"GUT"},{"key":"10.1002\/14651858.CD003685-BIB7|cit7","unstructured":"6 week placebo controlled study 137 patients (125mg rofecoxib, 175mg rofecoxib versus placebo) Centre for Drug Evaluation, Research (CDER017) plus extension"},{"key":"10.1002\/14651858.CD003685-BIB8|cit8","unstructured":"Phase IIb dose finding study 2 year duration, 634 patients comparing 25, 50 mg rofecoxib to naproxen, placebo Details in Konstam 2001"},{"key":"10.1002\/14651858.CD003685-BIB9|cit9","unstructured":"Phase III: domestic US 1 year duration 909 patients Comparing 125 25 50mg rofecoxib with naproxen placebo Details in Konstam 2001"},{"key":"10.1002\/14651858.CD003685-BIB10|cit10","unstructured":"Phase III endoscopy study 660 patients enrolled 13 week duration Rofecoxib 50mg compared to naproxen, placebo Details in Konstam 2001"},{"key":"10.1002\/14651858.CD003685-BIB11|cit11","unstructured":"Phase III international study 1058 enrolled, 1 year duration Rofecoxib 25, 50mg compared to naproxen, placebo Details in Konstam 2001"},{"key":"10.1002\/14651858.CD003685-BIB12|cit12","unstructured":"Measurement of clinical outcome within clinical service Ongoing study"},{"issue":"1","key":"10.1002\/14651858.CD003685-BIB13|cit13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000046212","article-title":"Renal effects of COX-2-selective inhibitors","volume":"21","author":"Brater","year":"2001","journal-title":"American Journal of Nephrology"},{"key":"10.1002\/14651858.CD003685-BIB14|cit14","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/0140-6736(90)90944-Z","article-title":"Blood presure, stroke and coronary disease, II: short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context","volume":"335","author":"Collins","year":"1990","journal-title":"Lancet"},{"issue":"Suppl 9","key":"10.1002\/14651858.CD003685-BIB15|cit15","first-page":"S143","article-title":"Cardiovascular safety profile of rofecoxib in controlled clinical trials","volume":"42","author":"Daniels","year":"1999","journal-title":"Arthritis & Rheumatism"},{"key":"10.1002\/14651858.CD003685-BIB16|cit16","unstructured":"FDA Advisory Committee Cardiovascular safety review of rofecoxib http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/01\/briefing\/3677b2_06_cardio.pdf"},{"key":"10.1002\/14651858.CD003685-BIB17|cit17","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/art.1780360601","article-title":"The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials","volume":"36","author":"Felson","year":"1993","journal-title":"Arthritis Rheum"},{"issue":"727-35","key":"10.1002\/14651858.CD003685-BIB18|cit18","article-title":"American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1002\/14651858.CD003685-BIB19|cit19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomised controlled trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.CD003685-BIB20|cit20","doi-asserted-by":"crossref","first-page":"r15","DOI":"10.1161\/hc4401.100078","article-title":"Cardiovascular thrombotic events in controlled clinical trials of rofecoxib","volume":"104","author":"Konstam","year":"2001","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD003685-BIB21|cit21","first-page":"526","article-title":"Conference on Outcome Measures in Rheumatoid Arthritis Clinical Trials","volume":"20","author":"OMERACT","year":"1993","journal-title":"J Rheumatol"},{"issue":"8","key":"10.1002\/14651858.CD003685-BIB22|cit22","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1002\/1529-0131(199908)42:8<1572::AID-ANR2>3.0.CO;2-G","article-title":"ACR20: clinical or statistical significance?","volume":"42","author":"Pincus","year":"1999","journal-title":"Arthritis Rheum"},{"issue":"9272","key":"10.1002\/14651858.CD003685-BIB23|cit23","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(00)05083-2","article-title":"Acute tubulointerstitial nephritis associated wiht the selective COX II enzyme inhibitor rofecoxib","volume":"357","author":"Rocha","year":"2001","journal-title":"The Lancet"},{"key":"10.1002\/14651858.CD003685-BIB24|cit24","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schulz","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD003685-BIB25|cit25","first-page":"811","volume-title":"Oxford Textbook of Rheumatology Rheumatology","author":"Silman","year":"1998"},{"key":"10.1002\/14651858.CD003685-BIB26|cit26","doi-asserted-by":"crossref","first-page":"241","DOI":"10.7326\/0003-4819-123-4-199508150-00001","article-title":"Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving NSAIDs: a randomised double-blind, placebo controlled trial","volume":"123","author":"Siverstein","year":"1995","journal-title":"Annals of Internal Medicine"},{"issue":"10","key":"10.1002\/14651858.CD003685-BIB27|cit27","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jama.284.10.1247","article-title":"Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study","volume":"284","author":"Silverstein","year":"2000","journal-title":"JAMA"},{"issue":"1","key":"10.1002\/14651858.CD003685-BIB28|cit28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-133-1-200007040-00002","article-title":"Effect of cyclooxygenase -2 inhibition on renal function in elderly persons receiving a low salt diet: a randomised controlled trial","volume":"133","author":"Swan","year":"2000","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD003685-BIB29|cit29","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1146\/annurev.pharmtox.38.1.97","article-title":"Cyclooxygenases 1 and 2","volume":"38","author":"Vane","year":"1998","journal-title":"Annual Review of Pharmacology & Toxicology"},{"key":"10.1002\/14651858.CD003685-BIB30|cit30","first-page":"2562","article-title":"Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis: a retrospective cohort study from disease onset","volume":"26","author":"Wallberg-Jonsson","year":"1999","journal-title":"Journal of Rheumatology"},{"issue":"2","key":"10.1002\/14651858.CD003685-BIB31|cit31","article-title":"Non-aspirin, non-steroidal anti-inflammatory drugs for osteoarthritis of the knee","author":"Watson","year":"2000","journal-title":"Cochrane Library"},{"issue":"85-95","key":"10.1002\/14651858.CD003685-BIB32|cit32","article-title":"Cyclo-oxygenase-2 specific inhibitors and cardio-renal function: a randomised controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients","volume":"8","author":"Whelton","year":"2001","journal-title":"American Journal of Therapeutics"}],"updated-by":[{"DOI":"10.1002\/14651858.cd003685.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2005,1,24]],"date-time":"2005-01-24T00:00:00Z","timestamp":1106524800000}}],"container-title":["The Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD003685\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T17:24:17Z","timestamp":1628529857000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD003685"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,7,22]]},"references-count":32,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd003685","relation":{},"subject":[],"published":{"date-parts":[[2002,7,22]]}}}